USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
28 Mar 2013 | North America | Market Research
Vital Signs - The Healthcare News - March Issue
This issue of Vital Signs, released on March 28, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Life Sciences and Advanced Medical Technology.
$1,500.00
Special Price $1,125.00 save 25 %
-
07 Mar 2013 | North America | Market Research
Vital Signs - Over the Patent Cliff: Suing the FDA is the Latest Action by Branded and Generics Pharmaceutical Companies Battling for Market Opportunity
This issue of Vital Signs, released on March 7, 2013, provides an insight in to battle between FDA and branded and generic pharmaceutical companies. Additionally, a company spotlight is provided for PLC Diagnostics. PLC Diagnostics is an early stage startup, developing the next generation of handheld point-of-care testing devices.
$1,500.00
Special Price $1,125.00 save 25 %
-
06 Mar 2013 | North America | Market Research
Frost & Sullivan Awards for Impact of Biomarkers (Technical Insights)
Breakthroughs in drug discovery have led to rich and competitive pipelines for rare diseases such as rare cancers as well as neurologic disorders and musculoskeletal disorders, among many other therapeutic areas. This research service provides a comprehensive global overview and analysis of global orphan drugs development, with an emphasis on the U...
$3,950.00
Special Price $2,962.50 save 25 %
-
04 Mar 2013 | North America | Market Research
Analysis of the U.S. Magnetic Resonance Imaging (MRI) Systems Market
An Assessment and Outlook through 2016
This research service evaluates the U.S. MRI systems market during the 2008 to 2016 time period. It provides analyses of the less than or equal to 1.5 Tesla and 3.0 Tesla market segments at the total market and individual segment levels. Content in this research service includes market background, technology trends, market drivers and restraints, a...
$4,950.00
Special Price $3,712.50 save 25 %
-
28 Feb 2013 | North America | Market Research
Vital Signs - Healthcare News - The Analysts Perspective - February Issue
This issue of Vital Signs, released on February 28, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Life Sciences and Advanced Medical Technology.
$1,500.00
Special Price $1,125.00 save 25 %
-
27 Feb 2013 | North America | Market Research
Vital Signs - The Middle Eastern Medical Imaging Informatics Market – Between Lure and Big Opportunity
This issue of Vital Signs, released on February 27, 2013, provides an insight in to the medical imaging market in the Middle East. It is a commentary on the annual Arab Health conference held in Dubai on Jan. 28-31, 2013, Additionally, a company spotlight is provided for NextGate. NextGate is a leading provider of Enterprise Master Patient Index (...
$1,500.00
Special Price $1,125.00 save 25 %
-
26 Feb 2013 | North America | Market Research
A Product and Pipeline Analysis of the U.S. Prostate Cancer Therapeutics Market
A New Era of Drug Development
This research service focuses on the current status of the prostate cancer therapeutics pipeline candidates with a focus on segmentation, current Phase 1-3 candidates and detailed clinical trial timelines. Prostate cancer incidence and three big predictions are also included in this research service.
$1,500.00
Special Price $1,125.00 save 25 %
-
18 Feb 2013 | North America | Market Research
Analysis of the European Hepatitis B and C Therapeutics Markets
Emerging Combinatorial Therapeutics is the Future Market
The marketed and development product landscape for diabetes therapeutics is becoming crowded with multiple products with little differentiation. However, there is still ample room for growth through the introduction of novel therapies that fill therapeutic gaps left by available products. Comprehensive information on market background and global ...
$4,950.00
Special Price $3,712.50 save 25 %
-
01 Feb 2013 | North America | Economic and Databases
Decision Support Database - Burden Of Disease And Conditions
Burden of Disease or Conditions Decision Support Database provides information on exhaustive list of Measurements on Incidence, Prevalence and Mortality for different types of Communicable and Non Communicable Disease.
$1,500.00
Special Price $1,125.00 save 25 %
-
23 Jan 2013 | North America | Market Research
Analysis of the European HIV Drugs Market
Increasing Adoption of Oral Combination-pills for Treatment Boosts Market Growth
Dyslipidemia exists in many forms and is prevalent in developed regions. Although many patients with moderately elevated lipids are well served by available therapies, there is a significant patient population for whom these therapies are inappropriate or inadequate, thereby prompting development of innovative therapies to fill the gaps. This res...
$4,950.00
Special Price $3,712.50 save 25 %
